BR9206593A - Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas - Google Patents

Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas

Info

Publication number
BR9206593A
BR9206593A BR9206593A BR9206593A BR9206593A BR 9206593 A BR9206593 A BR 9206593A BR 9206593 A BR9206593 A BR 9206593A BR 9206593 A BR9206593 A BR 9206593A BR 9206593 A BR9206593 A BR 9206593A
Authority
BR
Brazil
Prior art keywords
phase
particles
liquid crystalline
pct
preparing
Prior art date
Application number
BR9206593A
Other languages
English (en)
Inventor
Tomas Landh
Kare Larsson
Original Assignee
Gs Biochem Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gs Biochem Ab filed Critical Gs Biochem Ab
Priority claimed from PCT/SE1992/000692 external-priority patent/WO1993006921A1/en
Publication of BR9206593A publication Critical patent/BR9206593A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/02—Liquid crystal materials characterised by optical, electrical or physical properties of the components, in general
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/52—Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K19/54—Additives having no specific mesophase characterised by their chemical composition
    • C09K19/542—Macromolecular compounds
    • C09K19/544—Macromolecular compounds as dispersing or encapsulating medium around the liquid crystal
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/52—Liquid crystal materials characterised by components which are not liquid crystals, e.g. additives with special physical aspect: solvents, solid particles
    • C09K2019/528—Surfactants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/90—Liquid crystal material of, or for, colloid system, e.g. g phase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Colloid Chemistry (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BR9206593A 1991-10-04 1992-10-02 Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas BR9206593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77101491A 1991-10-04 1991-10-04
PCT/SE1992/000692 WO1993006921A1 (en) 1991-10-04 1992-10-02 Particles, method of preparing said particles and uses thereof

Publications (1)

Publication Number Publication Date
BR9206593A true BR9206593A (pt) 1995-11-28

Family

ID=25090424

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9206593A BR9206593A (pt) 1991-10-04 1992-10-02 Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas

Country Status (10)

Country Link
US (1) US5531925A (pt)
EP (1) EP0643620B1 (pt)
JP (1) JP3571717B2 (pt)
AT (1) ATE182278T1 (pt)
AU (1) AU2699892A (pt)
BR (1) BR9206593A (pt)
CA (1) CA2120359C (pt)
DE (1) DE69229640T2 (pt)
ES (1) ES2133391T3 (pt)
FI (1) FI941538A (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085827C (en) * 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
FR2726762B1 (fr) * 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
JPH08254688A (ja) * 1995-03-16 1996-10-01 Toshiba Corp 液晶表示素子
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
AU714584B2 (en) 1995-07-21 2000-01-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP0965336A1 (en) * 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US6284375B1 (en) * 1996-10-18 2001-09-04 Tuo Jin Lipid vesicle system
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6106609A (en) * 1997-04-08 2000-08-22 The United States Of America As Represented By The Secretary Of The Navy Formation of nanocrystalline semiconductor particles within a bicontinuous cubic phase
EP0875232B1 (en) * 1997-05-02 2002-02-13 Takasago International Corporation A lipid composition containing liquid crystal phase
US5962015A (en) * 1997-05-02 1999-10-05 Kobo Products S.A.R.L. Stabilized liposomes
TR199901008T1 (xx) * 1997-09-09 2000-02-21 Select Release, L.C. Kaplanm�� partik�ller, yap�m� ve kullan�m y�ntemleri.
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
SE9703458D0 (sv) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US6558961B1 (en) * 1998-09-04 2003-05-06 Powderject Research Limited Immunodiagnostics using particle delivery methods
CN1368874A (zh) * 1999-08-06 2002-09-11 马克斯－德尔布吕克分子医学研究所 可植入的生物活性物质储存体
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
WO2001093835A1 (en) * 2000-06-02 2001-12-13 Zycos Inc. Delivery systems for bioactive agents
US20020153508A1 (en) * 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US20040266983A1 (en) * 2000-08-17 2004-12-30 Reeve Lorraine E Purified polyoxyalkylene block copolymers
DE10057770A1 (de) * 2000-11-22 2002-05-23 Beiersdorf Ag Hautpflegeprodukte mit einem Gehalt an dispersen Flüssigkristallen, welche kubische Phasen darstellen ,
CA2428993C (en) * 2000-11-29 2011-05-31 Lyotropic Therapeutics, Inc. Solvent systems for pharmaceutical agents
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) * 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030060695A1 (en) * 2001-03-07 2003-03-27 Connelly Patrick R. Implantable artificial organ devices
WO2003000236A1 (en) * 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
EP1423175B1 (en) * 2001-08-08 2013-10-02 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20040022820A1 (en) * 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
EP1460897A4 (en) * 2001-12-10 2006-09-13 Spherics Inc PROCESSES AND PRODUCTS SUITED TO THE FORMATION AND ISOLATION OF MICROPARTICLES
ES2282628T3 (es) * 2002-04-23 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicon farmaceutica que contiene particulas de lamotrigina de morfologia definida.
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target
CA2488643A1 (en) * 2002-06-13 2003-12-24 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
AU2003258075A1 (en) * 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
WO2005014162A1 (en) * 2003-08-04 2005-02-17 Camurus Ab Method for improving the properties of amphiphile particles
WO2005021046A1 (en) * 2003-09-01 2005-03-10 Fh Faulding & Co Ltd Compositions and methods for delivery of biologically active agents
GB0322033D0 (en) * 2003-09-19 2003-10-22 Camurus Ab Composition
US20070293441A1 (en) * 2003-09-22 2007-12-20 Baxter International Inc. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
KR101133502B1 (ko) 2003-09-22 2012-04-24 박스터 헬쓰케어 에스.에이. 제약학적 제제를 최종 멸균처리하기 위한 고압 멸균법 및의료 제품
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
US8865021B2 (en) * 2003-11-07 2014-10-21 Camurus Ab Compositions of lipids and cationic peptides
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
WO2005070394A2 (en) 2004-01-23 2005-08-04 Camurus Ab Ternary non-lamellar lipid compositions
GB0401513D0 (en) * 2004-01-23 2004-02-25 Camurus Ab Compositions
EP1598060A1 (en) * 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
US8541400B2 (en) * 2004-08-04 2013-09-24 Camurus Ab Compositions forming non-lamellar dispersions
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
DE602005026998D1 (de) * 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
WO2006077362A1 (en) * 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
GB0501364D0 (en) * 2005-01-21 2005-03-02 Camurus Ab Compositions
US7125954B2 (en) 2005-01-27 2006-10-24 General Electric Company Method for producing polyether polymers
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
US20100047413A1 (en) * 2006-09-15 2010-02-25 Cabalka Tourtellotte Leanne M Method of using amphiphilic multiblock copolymers in food
CZ2006697A3 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
US9080973B2 (en) * 2009-04-22 2015-07-14 Wisconsin Alumni Research Foundation Analyte detection using liquid crystals
WO2013168172A1 (en) 2012-05-10 2013-11-14 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
ES2834318T3 (es) 2012-05-25 2021-06-17 Camurus Ab Formulaciones de agonistas de receptores de la somatostatina
CN111808276A (zh) * 2014-03-25 2020-10-23 豪夫迈·罗氏有限公司 制备用于细胞培养基中的泊洛沙姆的方法
CA3003397A1 (en) 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Delivery systems
WO2019241853A1 (en) 2018-06-21 2019-12-26 NanoMed Holdings Pty Ltd Platinum-based amphiphile prodrugs
US20230057782A1 (en) * 2020-02-03 2023-02-23 Curemast, Inc. Compositions and methods of use thereof for treatment of mastitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4556289A (en) * 1983-03-21 1985-12-03 Manchester R & D Partnership Low birefringence encapsulated liquid crystal and optical shutter using same
US5371109A (en) * 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
GB8803037D0 (en) * 1988-02-10 1988-03-09 Unilever Plc Aqueous detergent compositions & methods of forming them
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
JPH03139525A (ja) * 1989-10-24 1991-06-13 Sunstar Eng Inc 紫外線硬化性組成物

Also Published As

Publication number Publication date
EP0643620B1 (en) 1999-07-21
FI941538A0 (fi) 1994-03-31
ES2133391T3 (es) 1999-09-16
CA2120359C (en) 2000-12-26
AU2699892A (en) 1993-05-03
ATE182278T1 (de) 1999-08-15
JPH07502197A (ja) 1995-03-09
FI941538A (fi) 1994-05-31
CA2120359A1 (en) 1993-04-15
US5531925A (en) 1996-07-02
DE69229640D1 (de) 1999-08-26
DE69229640T2 (de) 1999-12-16
JP3571717B2 (ja) 2004-09-29
EP0643620A1 (en) 1995-03-22

Similar Documents

Publication Publication Date Title
BR9206593A (pt) Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas
RU2159761C2 (ru) Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
EP0221041A3 (en) Benzimidazole derivatives, process for their preparation and their pharmaceutical use
BG101118A (en) Therapeutical compounds
NO941191L (no) Partikler, fremgangsmåte for fremstilling samt anvendelse av slike
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
DE69425671D1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
DE69726577D1 (en) Kristallin form i von clarithromycin
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
KR950703954A (ko) 외상 손상과 관련된 신경학적 병변의 치료에서 릴루졸의 적용(application of riluzole in the treatment of neurological lesions related to traumatic injuries)
AR012717A1 (es) Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
BR9808812A (pt) Composição compreendendo partìculas cristalinas, finamente divididas de budesonida
CZ77995A3 (en) Derivatives of lipopeptides, process of their preparation and use
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
EP0137440A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
EP0137441A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
ES2193246T3 (es) Cefalosporinas antibacterianas.
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
EP0268223A3 (de) Optisch aktive Gyrasehemmer, ihre Herstellung und Verwendung als Antibiotika
FR2725718B1 (fr) Bis-2-aminopyridines, leur procede de preparation et leurs applications
EP0443957A3 (en) New 17-spiro substituted steroid compounds, process for their preparation and intermediates of this process, their use as medicines and pharmaceutical preparations containing them
NO307933B1 (no) Vann-uløselig eller lite vannløselig terapeutisk forbindelse, anvendelse derav samt farmasøytisk blanding inneholdende nevnte forbindelse
GR3035710T3 (en) Substituted benzenesulfonylureas and -thioureas, process for their preparation and the use of pharmaceutical preparations based on these compounds as well as medicaments containing them
IE43125L (en) Aminoglycoside derivative
EP0334281A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
EE Request for examination
PC Transfer
EG Technical examination (opinion): publication of technical examination (opinion)
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADE(S).

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2278 DE 02/09/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.